Biogen’s AdComm Meeting Will Test FDA’s “Substantial Evidence” Flexibility | Sue Sutter | 10/08/20 | Boston |
In RNAi Move, Takeda Fronts $300M to Team Up on Arrowhead Liver Drug | Frank Vinluan | 10/08/20 | National |
BIO Launches ‘Biotech Votes’ Campaign to Encourage Registration and Informed Voting | Editors | 10/08/20 | Boston |
Scribe Therapeutics Sets Out to Write CRISPR Gene Editing’s Next Chapter | Frank Vinluan | 10/06/20 | San Francisco |
Federation Bio Bags $50M to Engineer New Approach to Microbiome Drugs | Frank Vinluan | 10/06/20 | Boston |
Bristol Myers to Buy MyoKardia, FDA-Ready Heart Disease Drug for $13.1B | Frank Vinluan | 10/05/20 | New York |
Bristol Myers’s Hirawat on Pipeline Progress, Clinical Trial Diversity | Mandy Jackson | 10/02/20 | National |
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More | Frank Vinluan | 10/02/20 | National |
FDA Lifts Solid Bio Clinical Hold, Duchenne Study Cleared to Resume | Frank Vinluan | 10/01/20 | Boston |
Genfit Restructuring Cuts Staff by 40%, Creates Two New Subsidiaries | Frank Vinluan | 10/01/20 | Europe |
Pfizer Pumps $200M Into CStone for Rights to PD-L1 Cancer Drug in China | Frank Vinluan | 09/30/20 | New York |
With Phase 2 Data in Hand, Ovid Eyes Multiple Pivotal Trials for Epilepsy Drug | Frank Vinluan | 09/30/20 | New York |
Orphazyme Stock Sale Reaps $83M as Neimann-Pick Drug Review Begins | Frank Vinluan | 09/29/20 | Europe |
Praxis Precision Medicines Leads Way as Three More Biotechs Prep IPOs | Frank Vinluan | 09/28/20 | Boston |
Galecto Picks Up $64M as Plans for Fibrosis Clinical Trials Move Forward | Frank Vinluan | 09/25/20 | Europe |
Bio Roundup: Grail Acquisition, Libra’s Launch, Tau Trial Results & More | Frank Vinluan | 09/25/20 | National |
Combined Therapeutics Inc Wins $250,000 MilliporeSigma Advance Biotech Grant | Editors | 09/25/20 | National |
Monte Rosa Raises $96M for “Glue-Based” Protein Degrading Drugs | Frank Vinluan | 09/24/20 | Boston |
And the 2020 National Xconomy Awards Winners Are… | Editors | 09/24/20 | National |
Libra Strikes a Balance With Approach to ALS and Other Neuro Disorders | Frank Vinluan | 09/23/20 | San Diego |
Tau-Targeting Alzheimer’s Drug from AC Immune, Roche Fails in Phase 2 | Frank Vinluan | 09/23/20 | Europe |
Athira CEO Kawas: Alzheimer’s Drug Aims for “Recovery of Brain Function” | Frank Vinluan | 09/23/20 | Seattle |
Gene Therapy Firms Seek Clarity on FDA Exclusivity, Orphan Designations | Sue Sutter | 09/22/20 | National |
Xconomy Awards On-Demand ‘Meet the Finalists’ Webcast Series Continues This Week | Editors | 09/21/20 | Boston |
Illumina to Acquire Cancer Diagnostics Developer Grail in $8B Deal | Frank Vinluan | 09/21/20 | San Francisco |
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More | Frank Vinluan | 09/18/20 | National |
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D | Frank Vinluan | 09/17/20 | Boston |
BIO Chief: “Reckless” Executive Order on Drug Prices Threatens Innovation | Dan Stanton | 09/17/20 | Boston |
Finch Therapeutics Fetches $90M to Advance Microbiome Drug Pipeline | Frank Vinluan | 09/17/20 | Boston |
Arrowhead Pharma Shares Soar on Early Liver Data for RNAi Drug | Frank Vinluan | 09/16/20 | Wisconsin |